Urothelial Carcinoma

90% of bladder cancers are urothelial carcinomas icon
90% of bladder cancers are urothelial carcinomas icon

5-year relative survival rates have remained unchanged at1:

5-year survival rates for bladder cancer
5-year survival rates for bladder cancer
5 to 7 months icon
5 to 7 months icon

Most patients with advanced/metastatic UC progress on treatment with platinum-based chemotherapy and have a median overall survival of 5 to 7 months.4

In metastatic UC, Testing for PD-L1 expression can help identify patients who may be more likely to respond to anti–PD-1/PD-L1 therapy.5-9

In metastatic UC, Testing for PD-L1 expression can help identify patients who may be more likely to respond to anti–PD-1/PD-L1 therapy.5-9

Other biomarkers may help diagnose UC and monitor for recurrence.10

PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; UC, urothelial carcinoma.

 

References: 1. National Cancer Institute. http://seer.cancer.gov/statfacts/html/urinb.html. Accessed March 9, 2018. 2. Hall MC et al. J Urol. 2007;178(6):2314-2330. 3. American Cancer Society.  http://www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf. Updated May 23, 2016. Accessed March 9, 2018. 4. Bellmunt J et al. J Clin Oncol. 2009;27(27):4454-4461. 5. Massard C et al. J Clin Oncol. 2016;34(26):3119-3125. doi:10.1200/JCO.2016.67.9761. 6. Sharma P et al. Lancet Oncol. 2016;17(11):1590-1598. 7. Plimack ER et al. Lancet Oncol. 2017;18:212-220. 8. Rosenberg JE et al. Lancet. 2016;387(10031):1909-1920. 9. Powles T et al. Nature. 2014;515(7528):558-562. 10. Kamat AM et al; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. Eur Urol. 2013;63(1):4-15.